
Common Cold Market
Description
Common Cold Market Report and Forecast 2024-2032
The common cold market was valued at USD 8.3 billion in 2023 driven by increasing incidence of common cold and growing preventive healthcare products across the 8 major markets. It is expected to grow at a CAGR of 8.7% during the forecast period 2024-2032 and attain a market value of USD 18.7 billion by 2032.
Common Cold Market Analysis
The common cold is a viral infection that primarily affects the upper respiratory tract, causing symptoms such as a runny nose, cough, sneezing, sore throat, and congestion. It is usually caused by rhinoviruses and is highly contagious, spreading through respiratory droplets or direct contact. Although the common cold is typically mild and self-limiting, it can cause discomfort and lead to secondary infections in some cases. Treatments focus on symptom relief, with a range of over-the-counter medications available, including antihistamines, decongestants, and expectorants.
Market Drivers
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Common Cold Market Segmentation
Market Breakup by Drug Class
Market Breakup by Doses
Market Breakup by Distribution Channel
Market Breakup by Region
Common Cold Market Competitive Landscape
The competitive landscape of the common cold market includes key players such as Reckitt Benckiser Group PLC, Johnson & Johnson, GSK plc, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Procter & Gamble Health Limited, Sanofi, and Haleon Group. These companies focus on continuous innovation in product formulations, including the development of multi-symptom remedies and natural alternatives. Strategic partnerships, mergers, and acquisitions are common strategies to expand market share and strengthen product portfolios. The increasing focus on e-commerce and digital marketing is helping these firms reach a wider consumer base, particularly in emerging markets.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the common cold market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the common cold market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the common cold industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The common cold market was valued at USD 8.3 billion in 2023 driven by increasing incidence of common cold and growing preventive healthcare products across the 8 major markets. It is expected to grow at a CAGR of 8.7% during the forecast period 2024-2032 and attain a market value of USD 18.7 billion by 2032.
Common Cold Market Analysis
The common cold is a viral infection that primarily affects the upper respiratory tract, causing symptoms such as a runny nose, cough, sneezing, sore throat, and congestion. It is usually caused by rhinoviruses and is highly contagious, spreading through respiratory droplets or direct contact. Although the common cold is typically mild and self-limiting, it can cause discomfort and lead to secondary infections in some cases. Treatments focus on symptom relief, with a range of over-the-counter medications available, including antihistamines, decongestants, and expectorants.
Market Drivers
- High Prevalence of the Common Cold: The common cold is one of the most frequent human illnesses, affecting millions worldwide each year. Its widespread prevalence continues to drive demand for over-the-counter medications that alleviate symptoms and improve patient comfort.
- Increased Consumer Awareness of Cold Relief Products: With the growing awareness of health and wellness, consumers are more proactive in seeking treatment for cold symptoms. This trend drives demand for various remedies, including natural supplements and OTC medications, contributing to market expansion.
- Rise in Self-Medication Practices: Consumers are increasingly turning to self-medication for common cold symptoms, especially in regions with easy access to over-the-counter medications. This shift towards self-care contributes to the growing demand for cold relief products.
- Growing Healthcare Expenditure: Increasing healthcare expenditure globally, particularly in emerging markets, is improving access to treatments for common illnesses like the cold. This expanded access to prescription and OTC medications boosts the demand for cold remedies.
- Expansion of E-Commerce Channels: The rise of e-commerce platforms is making it easier for consumers to purchase medications for cold relief online. This trend is particularly pronounced in the wake of the COVID-19 pandemic, which has accelerated the shift towards digital health and online pharmacies.
- Side Effects of Cold Medications: Some cold medications, particularly antihistamines and decongestants, can cause unwanted side effects such as drowsiness, dizziness, or increased heart rate. These side effects may deter consumers from using certain products or lead to concerns about safety.
- High Competition from Natural Remedies: There is increasing competition from natural and homeopathic remedies that claim to offer relief from cold symptoms. These alternatives often appeal to health-conscious consumers, who may prefer herbal supplements or natural treatments over traditional pharmaceuticals.
- Regulatory Restrictions on Cold Medications: The regulation of cold medications, particularly for over-the-counter products, can vary by region. In some cases, restrictions on the sale of decongestants or other ingredients limit access to certain products, creating challenges for manufacturers and distributors.
- Seasonal Nature of the Common Cold: The common cold is highly seasonal, with most cases occurring during the colder months. This seasonal nature can lead to fluctuations in demand for cold medications, making it difficult for manufacturers to maintain consistent sales throughout the year.
- Development of Combination Therapies: There is growing interest in combination therapies that provide multi-symptom relief for the common cold. These products, which combine antihistamines, decongestants, and pain relievers, offer a convenient solution for consumers and present opportunities for product innovation.
- Expansion into Emerging Markets: Emerging markets in Asia Pacific and Latin America present significant growth opportunities for common cold medications. As healthcare infrastructure improves and disposable income rises, more consumers in these regions are gaining access to OTC cold remedies.
- Increased Demand for Natural and Herbal Products: The rising consumer preference for natural and herbal treatments is creating opportunities for the development of cold medications that incorporate plant-based ingredients. These products appeal to health-conscious consumers seeking gentler, more natural remedies.
- Technological Advances in Drug Delivery: Innovations in drug delivery, such as fast-dissolving tablets and extended-release formulations, are providing new opportunities for cold medications. These technologies offer more convenient dosing options and can improve patient adherence to treatment regimens.
- Growth of Online Pharmacies: The increasing popularity of online pharmacies presents opportunities for manufacturers to expand their distribution networks. By offering cold medications through e-commerce platforms, companies can reach a broader customer base and cater to the growing demand for convenient, home-delivered healthcare products.
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Shift Towards Natural and Organic Products
- Increasing Use of Combination Cold Medications
- Growth in Preventive Health Measures
- Expansion of E-Commerce and Online Pharmacies
- Increasing Demand for Convenient and Fast-Acting Formulations
- Rising Focus on Innovative Packaging
Common Cold Market Segmentation
Market Breakup by Drug Class
- Antihistamines
- Expectorants
- Bronchodilators
- Decongestants
- Antibiotics
- Others
Market Breakup by Doses
- Oral Syrups
- Tablets/Pills
- Nasal Drops
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Common Cold Market Competitive Landscape
The competitive landscape of the common cold market includes key players such as Reckitt Benckiser Group PLC, Johnson & Johnson, GSK plc, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Procter & Gamble Health Limited, Sanofi, and Haleon Group. These companies focus on continuous innovation in product formulations, including the development of multi-symptom remedies and natural alternatives. Strategic partnerships, mergers, and acquisitions are common strategies to expand market share and strengthen product portfolios. The increasing focus on e-commerce and digital marketing is helping these firms reach a wider consumer base, particularly in emerging markets.
Key Questions Answered in the Report
- What are the major drivers contributing to the growth of the common cold market?
- How is the shift towards natural and organic products impacting the common cold market?
- What are the primary challenges faced by manufacturers in developing effective cold treatments?
- How is the rise of online pharmacies influencing the distribution of cold relief products?
- What are the trends driving the demand for combination therapies in cold medications?
- How are e-commerce and digital channels reshaping the sales of cold medications?
- What opportunities exist for pharmaceutical companies in emerging markets for cold treatments?
- How are innovative drug delivery systems improving convenience and patient adherence?
- What are the implications of seasonal demand fluctuations on the common cold market?
- How are competitive strategies such as mergers and partnerships shaping the common cold market?
- What is the role of preventive health products in the common cold treatment landscape?
- How are regulatory frameworks affecting the availability and distribution of cold medications?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the common cold market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the common cold market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the common cold industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Common Cold Market Overview – 8 Major Markets
- 3.1 Common Cold Market Historical Value (2017-2023)
- 3.2 Common Cold Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Common Cold Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Common Cold Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU-4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 U.S.
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU-4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 U.S.
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU-4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Common Cold Market Landscape – 8 Major Markets
- 8.1 Common Cold Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Common Cold Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Doses
- 9 Common Cold Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Common Cold Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Common Cold Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Common Cold Market (2018-2034) by Drug Class
- 12.1.1 Market Overview
- 12.1.2 Antihistamines
- 12.1.3 Expectorants
- 12.1.4 Bronchodilators
- 12.1.5 Decongestants
- 12.1.6 Antibiotics
- 12.1.7 Others
- 12.2 Common Cold Market (2018-2034) by Doses
- 12.2.1 Market Overview
- 12.2.2 Oral Syrups
- 12.2.3 Tablets/Pills
- 12.2.4 Nasal Drops
- 12.2.5 Others
- 12.3 Common Cold Market (2018-2034) by Distribution Channel
- 12.3.1 Market Overview
- 12.3.2 Hospital Pharmacies
- 12.3.3 Independent Pharmacies
- 12.3.4 Online Pharmacies
- 12.3.5 Others
- 12.4 Common Cold Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Common Cold Market (2018-2034)
- 13.1 United States Common Cold Market Historical Value (2017-2023)
- 13.2 United States Common Cold Market Forecast Value (2024-2032)
- 13.3 United States Common Cold Market (2018-2034) by Drug Class
- 13.3.1 Market Overview
- 13.3.2 Antihistamines
- 13.3.3 Expectorants
- 13.3.4 Bronchodilators
- 13.3.5 Decongestants
- 13.3.6 Antibiotics
- 13.3.7 Others
- 13.4 United States Common Cold Market (2018-2034) by Doses
- 13.4.1 Market Overview
- 13.4.2 Oral Syrups
- 13.4.3 Tablets/Pills
- 13.4.4 Nasal Drops
- 13.4.5 Others
- 13.5 United States Common Cold Market (2018-2034) by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacies
- 13.5.3 Independent Pharmacies
- 13.5.4 Online Pharmacies
- 13.5.5 Others
- 14 EU-4 and United Kingdom Common Cold Market (2018-2034)
- 14.1 EU-4 and United Kingdom Common Cold Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Common Cold Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Common Cold Market (2018-2034) by Drug Class
- 14.3.1 Market Overview
- 14.3.2 Antihistamines
- 14.3.3 Expectorants
- 14.3.4 Bronchodilators
- 14.3.5 Decongestants
- 14.3.6 Antibiotics
- 14.3.7 Others
- 14.4 EU-4 and United Kingdom Common Cold Market (2018-2034) by Doses
- 14.4.1 Market Overview
- 14.4.2 Oral Syrups
- 14.4.3 Tablets/Pills
- 14.4.4 Nasal Drops
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Common Cold Market (2018-2034) by Distribution Channel
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacies
- 14.5.3 Independent Pharmacies
- 14.5.4 Online Pharmacies
- 14.5.5 Others
- 15 Japan Common Cold Market
- 15.1 Japan Common Cold Market Historical Value (2017-2023)
- 15.2 Japan Common Cold Market Forecast Value (2024-2032)
- 15.3 Japan Common Cold Market (2018-2034) by Drug Class
- 15.3.1 Market Overview
- 15.3.2 Antihistamines
- 15.3.3 Expectorants
- 15.3.4 Bronchodilators
- 15.3.5 Decongestants
- 15.3.6 Antibiotics
- 15.3.7 Others
- 15.4 Japan Common Cold Market (2018-2034) by Doses
- 15.4.1 Market Overview
- 15.4.2 Oral Syrups
- 15.4.3 Tablets/Pills
- 15.4.4 Nasal Drops
- 15.4.5 Others
- 15.5 Japan Common Cold Market (2018-2034) by Distribution Channel
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacies
- 15.5.3 Independent Pharmacies
- 15.5.4 Online Pharmacies
- 15.5.5 Others
- 16 India Common Cold Market
- 16.1 India Common Cold Market Historical Value (2017-2023)
- 16.2 India Common Cold Market Forecast Value (2024-2032)
- 16.3 India Common Cold Market (2018-2034) by Drug Class
- 16.3.1 Market Overview
- 16.3.2 Antihistamines
- 16.3.3 Expectorants
- 16.3.4 Bronchodilators
- 16.3.5 Decongestants
- 16.3.6 Antibiotics
- 16.3.7 Others
- 16.4 India Common Cold Market (2018-2034) by Doses
- 16.4.1 Market Overview
- 16.4.2 Oral Syrups
- 16.4.3 Tablets/Pills
- 16.4.4 Nasal Drops
- 16.4.5 Others
- 16.5 India Common Cold Market (2018-2034) by Distribution Channel
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacies
- 16.5.3 Independent Pharmacies
- 16.5.4 Online Pharmacies
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 India CDSCO
- 17.5 Japan PMDA
- 18 Patent Analysis
- 18.1 Analysis by Drug Class of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Distribution Channel
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Reckitt Benckiser Group PLC
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Johnson & Johnson
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 GSK plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Novartis AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Bayer AG
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 Sun Pharmaceutical Industries. Ltd.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Pfizer Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Procter & Gamble Health Limited
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Sanofi
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 Haleon Group
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 24 Common Cold Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- *The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.